Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2000 Dec;37(12):897–904. doi: 10.1136/jmg.37.12.897

Neurofibromatosis type 2

D Evans 1, M Sainio 1, M Baser 1
PMCID: PMC1734496  PMID: 11106352

Abstract

Neurofibromatosis type 2 is an often devastating autosomal dominant disorder which, until relatively recently, was confused with its more common namesake neurofibromatosis type 1. Subjects who inherit a mutated allele of the NF2 gene inevitably develop schwannomas, affecting particularly the superior vestibular branch of the 8th cranial nerve, usually bilaterally. Meningiomas and other benign central nervous system tumours such as ependymomas are other common features. Much of the morbidity from these tumours results from their treatment. It is now possible to identify the NF2 mutation in most families, although about 20% of apparently sporadic cases are actually mosaic for their mutation. As a classical tumour suppressor, inactivation of the NF2 gene product, merlin/schwannomin, leads to the development of both NF2 associated and sporadic tumours. Merlin/schwannomin associates with proteins at the cell cytoskeleton near the plasma membrane and it inhibits cell proliferation, adhesion, and migration.


Keywords: NF2; vestibular schwannomma; meningioma; mosaic

Full Text

The Full Text of this article is available as a PDF (159.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J., Eldridge R., Koerber T. Acoustic neuroma in the last months of pregnancy. Am J Obstet Gynecol. 1974 Jun 15;119(4):516–520. doi: 10.1016/0002-9378(74)90212-9. [DOI] [PubMed] [Google Scholar]
  2. Antinheimo J., Haapasalo H., Haltia M., Tatagiba M., Thomas S., Brandis A., Sainio M., Carpen O., Samii M., Jäskeläinen J. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg. 1997 Oct;87(4):610–614. doi: 10.3171/jns.1997.87.4.0610. [DOI] [PubMed] [Google Scholar]
  3. Antinheimo J., Sankila R., Carpén O., Pukkala E., Sainio M., Jäskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000 Jan 11;54(1):71–76. doi: 10.1212/wnl.54.1.71. [DOI] [PubMed] [Google Scholar]
  4. Baser M. E., Evans D. G., Jackler R. K., Sujansky E., Rubenstein A. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000 Feb;82(4):998–998. doi: 10.1054/bjoc.1999.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baser M. E., Mautner V. F., Ragge N. K., Nechiporuk A., Riccardi V. M., Klein J., Sainz J., Pulst S. M. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology. 1996 Nov;47(5):1269–1277. doi: 10.1212/wnl.47.5.1269. [DOI] [PubMed] [Google Scholar]
  6. Baser M. E., Ragge N. K., Riccardi V. M., Janus T., Gantz B., Pulst S. M. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet. 1996 Sep 6;64(4):563–567. doi: 10.1002/(SICI)1096-8628(19960906)64:4<563::AID-AJMG7>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  7. Bijlsma E. K., Wallace A. J., Evans D. G. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet. 1997 Nov;34(11):934–936. doi: 10.1136/jmg.34.11.934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bourn D., Carter S. A., Evans D. G., Goodship J., Coakham H., Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet. 1994 Jul;55(1):69–73. [PMC free article] [PubMed] [Google Scholar]
  9. Bourn D., Carter S. A., Mason S., Gareth D., Evans R., Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet. 1994 May;3(5):813–816. doi: 10.1093/hmg/3.5.813. [DOI] [PubMed] [Google Scholar]
  10. Bouzas E. A., Parry D. M., Eldridge R., Kaiser-Kupfer M. I. Visual impairment in patients with neurofibromatosis 2. Neurology. 1993 Mar;43(3 Pt 1):622–623. doi: 10.1212/wnl.43.3_part_1.622. [DOI] [PubMed] [Google Scholar]
  11. Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999 Feb;11(1):109–116. doi: 10.1016/s0955-0674(99)80013-1. [DOI] [PubMed] [Google Scholar]
  12. Evans D. G., Birch J. M., Ramsden R. T. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999 Dec;81(6):496–499. doi: 10.1136/adc.81.6.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Evans D. G., Blair V., Strachan T., Lye R. H., Ramsden R. T. Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females. J Laryngol Otol. 1995 Sep;109(9):830–835. doi: 10.1017/s0022215100131445. [DOI] [PubMed] [Google Scholar]
  14. Evans D. G., Bourn D., Wallace A., Ramsden R. T., Mitchell J. D., Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet. 1995 Jun;32(6):470–474. doi: 10.1136/jmg.32.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  16. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Strachan T., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992 Dec;29(12):847–852. doi: 10.1136/jmg.29.12.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Evans D. G., Lye R., Neary W., Black G., Strachan T., Wallace A., Ramsden R. T. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):764–767. doi: 10.1136/jnnp.66.6.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Evans D. G., Maher E. R., Macleod R., Davies D. R., Craufurd D. Uptake of genetic testing for cancer predisposition. J Med Genet. 1997 Sep;34(9):746–748. doi: 10.1136/jmg.34.9.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Evans D. G., Mason S., Huson S. M., Ponder M., Harding A. E., Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):361–366. doi: 10.1136/jnnp.62.4.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Evans D. G., Newton V., Neary W., Baser M. E., Wallace A., Macleod R., Jenkins J. P., Gillespie J., Ramsden R. T. Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet. 2000 Dec;37(12):944–947. doi: 10.1136/jmg.37.12.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Evans D. G., Ramsden R., Huson S. M., Harris R., Lye R., King T. T. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993 May;107(5):401–406. doi: 10.1017/s002221510012328x. [DOI] [PubMed] [Google Scholar]
  23. Evans D. G., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998 Jun;35(6):450–455. doi: 10.1136/jmg.35.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Evans D. G., Wallace A. J., Wu C. L., Trueman L., Ramsden R. T., Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998 Sep;63(3):727–736. doi: 10.1086/512074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Fucci M. J., Buchman C. A., Brackmann D. E., Berliner K. I. Acoustic tumor growth: implications for treatment choices. Am J Otol. 1999 Jul;20(4):495–499. [PubMed] [Google Scholar]
  26. Grönholm M., Sainio M., Zhao F., Heiska L., Vaheri A., Carpén O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci. 1999 Mar;112(Pt 6):895–904. doi: 10.1242/jcs.112.6.895. [DOI] [PubMed] [Google Scholar]
  27. Gutmann D. H., Aylsworth A., Carey J. C., Korf B., Marks J., Pyeritz R. E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997 Jul 2;278(1):51–57. [PubMed] [Google Scholar]
  28. Gutmann D. H., Geist R. T., Xu H. m., Kim J. S., Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet. 1998 Mar;7(3):335–345. doi: 10.1093/hmg/7.3.335. [DOI] [PubMed] [Google Scholar]
  29. Gutmann D. H., Giordano M. J., Fishback A. S., Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology. 1997 Jul;49(1):267–270. doi: 10.1212/wnl.49.1.267. [DOI] [PubMed] [Google Scholar]
  30. Gutmann D. H., Sherman L., Seftor L., Haipek C., Hoang Lu K., Hendrix M. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet. 1999 Feb;8(2):267–275. doi: 10.1093/hmg/8.2.267. [DOI] [PubMed] [Google Scholar]
  31. Halliday A. L., Sobel R. A., Martuza R. L. Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg. 1991 Feb;74(2):248–253. doi: 10.3171/jns.1991.74.2.0248. [DOI] [PubMed] [Google Scholar]
  32. Hiscox S., Jiang W. G. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci. 1999 Sep;112(Pt 18):3081–3090. doi: 10.1242/jcs.112.18.3081. [DOI] [PubMed] [Google Scholar]
  33. Honda M., Arai E., Sawada S., Ohta A., Niimura M. Neurofibromatosis 2 and neurilemmomatosis gene are identical. J Invest Dermatol. 1995 Jan;104(1):74–77. doi: 10.1111/1523-1747.ep12613537. [DOI] [PubMed] [Google Scholar]
  34. Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381. doi: 10.1093/brain/111.6.1355. [DOI] [PubMed] [Google Scholar]
  35. Huynh D. P., Mautner V., Baser M. E., Stavrou D., Pulst S. M. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol. 1997 Apr;56(4):382–390. doi: 10.1097/00005072-199704000-00007. [DOI] [PubMed] [Google Scholar]
  36. Irving R. M., Moffat D. A., Hardy D. G., Barton D. E., Xuereb J. H., Holland F. J., Maher E. R. A molecular, clinical, and immunohistochemical study of vestibular schwannoma. Otolaryngol Head Neck Surg. 1997 Apr;116(4):426–430. doi: 10.1016/S0194-59989770289-4. [DOI] [PubMed] [Google Scholar]
  37. Jacoby L. B., Jones D., Davis K., Kronn D., Short M. P., Gusella J., MacCollin M. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997 Dec;61(6):1293–1302. doi: 10.1086/301633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kaiser-Kupfer M. I., Freidlin V., Datiles M. B., Edwards P. A., Sherman J. L., Parry D., McCain L. M., Eldridge R. The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol. 1989 Apr;107(4):541–544. doi: 10.1001/archopht.1989.01070010555030. [DOI] [PubMed] [Google Scholar]
  39. Kanter W. R., Eldridge R., Fabricant R., Allen J. C., Koerber T. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980 Aug;30(8):851–859. doi: 10.1212/wnl.30.8.851. [DOI] [PubMed] [Google Scholar]
  40. Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Fünsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. doi: 10.1007/s004390050255. [DOI] [PubMed] [Google Scholar]
  41. Kluwe L., MacCollin M., Tatagiba M., Thomas S., Hazim W., Haase W., Mautner V. F. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998 May 18;77(3):228–233. [PubMed] [Google Scholar]
  42. Kluwe L., Mautner V. F. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998 Dec;7(13):2051–2055. doi: 10.1093/hmg/7.13.2051. [DOI] [PubMed] [Google Scholar]
  43. Kondziolka D., Lunsford L. D., McLaughlin M. R., Flickinger J. C. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998 Nov 12;339(20):1426–1433. doi: 10.1056/NEJM199811123392003. [DOI] [PubMed] [Google Scholar]
  44. MacCollin M., Ramesh V., Jacoby L. B., Louis D. N., Rubio M. P., Pulaski K., Trofatter J. A., Short M. P., Bove C., Eldridge R. Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet. 1994 Aug;55(2):314–320. [PMC free article] [PubMed] [Google Scholar]
  45. Maeda M., Matsui T., Imamura M., Tsukita S., Tsukita S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene. 1999 Aug 26;18(34):4788–4797. doi: 10.1038/sj.onc.1202871. [DOI] [PubMed] [Google Scholar]
  46. Martuza R. L., Ojemann R. G. Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery. 1982 Jan;10(1):1–12. [PubMed] [Google Scholar]
  47. Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. doi: 10.1097/00006123-199605000-00004. [DOI] [PubMed] [Google Scholar]
  48. Mautner V. F., Lindenau M., Baser M. E., Kluwe L., Gottschalk J. Skin abnormalities in neurofibromatosis 2. Arch Dermatol. 1997 Dec;133(12):1539–1543. [PubMed] [Google Scholar]
  49. Mautner V. F., Tatagiba M., Guthoff R., Samii M., Pulst S. M. Neurofibromatosis 2 in the pediatric age group. Neurosurgery. 1993 Jul;33(1):92–96. doi: 10.1227/00006123-199307000-00014. [DOI] [PubMed] [Google Scholar]
  50. Mautner V. F., Tatagiba M., Lindenau M., Fünsterer C., Pulst S. M., Baser M. E., Kluwe L., Zanella F. E. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol. 1995 Oct;165(4):951–955. doi: 10.2214/ajr.165.4.7676998. [DOI] [PubMed] [Google Scholar]
  51. McGaughran J. M., Harris D. I., Donnai D., Teare D., MacLeod R., Westerbeek R., Kingston H., Super M., Harris R., Evans D. G. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999 Mar;36(3):197–203. [PMC free article] [PubMed] [Google Scholar]
  52. Mérel P., Hoang-Xuan K., Sanson M., Bijlsma E., Rouleau G., Laurent-Puig P., Pulst S., Baser M., Lenoir G., Sterkers J. M. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. doi: 10.1002/gcc.2870120206. [DOI] [PubMed] [Google Scholar]
  53. Narod S. A., Parry D. M., Parboosingh J., Lenoir G. M., Ruttledge M., Fischer G., Eldridge R., Martuza R. L., Frontali M., Haines J. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet. 1992 Sep;51(3):486–496. [PMC free article] [PubMed] [Google Scholar]
  54. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  55. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  56. Ragge N. K., Baser M. E., Klein J., Nechiporuk A., Sainz J., Pulst S. M., Riccardi V. M. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol. 1995 Nov;120(5):634–641. doi: 10.1016/s0002-9394(14)72210-x. [DOI] [PubMed] [Google Scholar]
  57. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  58. Rouleau G. A., Wertelecki W., Haines J. L., Hobbs W. J., Trofatter J. A., Seizinger B. R., Martuza R. L., Superneau D. W., Conneally P. M., Gusella J. F. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987 Sep 17;329(6136):246–248. doi: 10.1038/329246a0. [DOI] [PubMed] [Google Scholar]
  59. Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed] [Google Scholar]
  60. Ruttledge M. H., Narod S. A., Dumanski J. P., Parry D. M., Eldridge R., Wertelecki W., Parboosingh J., Faucher M. C., Lenoir G. M., Collins V. P. Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology. 1993 Sep;43(9):1753–1760. doi: 10.1212/wnl.43.9.1753. [DOI] [PubMed] [Google Scholar]
  61. Sainio M., Zhao F., Heiska L., Turunen O., den Bakker M., Zwarthoff E., Lutchman M., Rouleau G. A., Jäskeläinen J., Vaheri A. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci. 1997 Sep;110(Pt 18):2249–2260. doi: 10.1242/jcs.110.18.2249. [DOI] [PubMed] [Google Scholar]
  62. Sainz J., Figueroa K., Baser M. E., Mautner V. F., Pulst S. M. High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. Hum Mol Genet. 1995 Jan;4(1):137–139. doi: 10.1093/hmg/4.1.137. [DOI] [PubMed] [Google Scholar]
  63. Seizinger B. R., Martuza R. L., Gusella J. F. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986 Aug 14;322(6080):644–647. doi: 10.1038/322644a0. [DOI] [PubMed] [Google Scholar]
  64. Seizinger B. R., Rouleau G. A., Ozelius L. J., Lane A. H., Faryniarz A. G., Chao M. V., Huson S., Korf B. R., Parry D. M., Pericak-Vance M. A. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987 Jun 5;49(5):589–594. doi: 10.1016/0092-8674(87)90534-4. [DOI] [PubMed] [Google Scholar]
  65. Sherman L., Xu H. M., Geist R. T., Saporito-Irwin S., Howells N., Ponta H., Herrlich P., Gutmann D. H. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene. 1997 Nov 13;15(20):2505–2509. doi: 10.1038/sj.onc.1201418. [DOI] [PubMed] [Google Scholar]
  66. Slattery W. H., 3rd, Brackmann D. E., Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998 Sep;19(5):638–643. [PubMed] [Google Scholar]
  67. Sobel R. A. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993 Mar;52(2):106–113. doi: 10.1097/00005072-199303000-00002. [DOI] [PubMed] [Google Scholar]
  68. Thomas P. K., King R. H., Chiang T. R., Scaravilli F., Sharma A. K., Downie A. W. Neurofibromatous neuropathy. Muscle Nerve. 1990 Feb;13(2):93–101. doi: 10.1002/mus.880130202. [DOI] [PubMed] [Google Scholar]
  69. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  70. Tsukita S., Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem. 1999 Dec 3;274(49):34507–34510. doi: 10.1074/jbc.274.49.34507. [DOI] [PubMed] [Google Scholar]
  71. Watson C. J., Gaunt L., Evans G., Patel K., Harris R., Strachan T. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet. 1993 Jun;2(6):701–704. doi: 10.1093/hmg/2.6.701. [DOI] [PubMed] [Google Scholar]
  72. Wolff R. K., Frazer K. A., Jackler R. K., Lanser M. J., Pitts L. H., Cox D. R. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors. Am J Hum Genet. 1992 Sep;51(3):478–485. [PMC free article] [PubMed] [Google Scholar]
  73. Xu H. M., Gutmann D. H. Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res. 1998 Feb 1;51(3):403–415. doi: 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  74. Zang K. D. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet. 1982 Jul;6(3):249–274. doi: 10.1016/0165-4608(82)90063-2. [DOI] [PubMed] [Google Scholar]
  75. Zucman-Rossi J., Legoix P., Der Sarkissian H., Cheret G., Sor F., Bernardi A., Cazes L., Giraud S., Ollagnon E., Lenoir G. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet. 1998 Dec;7(13):2095–2101. doi: 10.1093/hmg/7.13.2095. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES